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RESEARCH ARTICLE
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Abstract
The 5’ non-translated region (NTR) is an important molecular determinant that controls repli-
cation and virulence of coxsackievirus B (CVB)3. Previous studies have reported many
nucleotide (nt) sequence differences in the Nancy strain of the virus, including changes in
the 5’ NTR with varying degrees of disease severity. In our studies of CVB3-induced myo-
carditis, we sought to generate an infectious clone of the virus for routine in vivo experimen-
tation. By determining the viral nt sequence, we identified three new nt substitutions in the
clone that differed from the parental virus strain: C97U in the 5’ NTR; a silent mutation,
A4327G, in non-structural protein 2C; and C5088U (resulting in P1449L amino acid change)
in non-structural protein 3A of the virus leading us to evaluate the role of these changes in
the virulence properties of the virus. We noted that the disease-inducing ability of the infec-
tious clone-derived virus in three mouse strains was restricted to pancreatitis alone, and the
incidence and severity of myocarditis were significantly reduced. We then reversed the
mutations by creating three new clones, representing 1) U97C; 2) G4327A and U5088C;
and 3) their combination together in the third clone. The viral titers obtained from all the
clones were comparable, but the virions derived from the third clone induced myocarditis
comparable to that induced by wild type virus; however, the pancreatitis-inducing ability
remained unaltered, suggesting that the mutations described above selectively influence
myocarditogenicity. Because the accumulation of mutations during passages is a continu-
ous process in RNA viruses, it is possible that CVB3 viruses containing such altered nts
may evolve naturally, thus favoring their survival in the environment.
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Introduction
Coxsackievirus B (CVB) is a positive-sense, single-stranded RNA virus belonging to the picor-
naviridae family [1,2]. CVB3, one of the six serotypes of the virus, commonly causes myocardi-
tis and pancreatitis in affected individuals. The viral genome codes for a large polyprotein,
which is proteolytically processed to generate the structural viral proteins (VP) 1, VP2, VP3,
and VP4, and several nonstructural (NS) proteins [3]. The structural proteins are involved in
the assembly of infectious virions, while the NS proteins are required for processing of the viral
polyprotein and genome replication [3–5]. The viral genome lacks a 5’ cap structure that is
required for translation and typically seen in most eukaryotic and many viral mRNAs [6,7].
Instead, the 5’ non-translated region (NTR) of the CVB3 genome contains an internal ribo-
some entry site, which mediates translation of viral mRNAs [8,9]. The 5’NTR, accounting for
10% of the CVB3 genome [742 out of 7400 nucleotides (nts)], forms multiple secondary stem-
loop structures and is known to harbor molecular determinants of viral pathogenicity [10–12].
For example, chimeric viruses resulting from replacement of the 5’NTRs of CVB3 with corre-
sponding regions from other viruses within the Enterovirus genus, such as echovirus and polio-
virus, have been shown to exhibit reduced growth characteristics in permissive cell lines and/or
lose pathogenicity [13,14].
Because CVB3 is an RNA virus and the viral RNA-dependent RNA polymerase lacks proof-
reading activity [15], the viral genome is prone to errors. Several clinical isolates containing sin-
gle and/or multiple nt changes have been reported with varying degrees of pathogenicity [16–
21]. Experimentally, the Nancy strain of CVB3 is commonly used to study the immune mecha-
nisms of viral myocarditis in various mouse models [22–25]. Our laboratory has been using
CVB3 (Nancy strain procured from the American Type Culture Collection [ATCC]) to exam-
ine the molecular determinants of myocarditis induced by virus in myocarditis-susceptible A/J
mice [23]. Because of the high error rate noted in the RNA viruses [26], we reasoned that the
CVB3 genome might have undergone point mutation(s) during continuous passage under
experimental conditions that could potentially alter viral pathogenicity in vivo. Therefore, we
sought to derive an infectious clone of the viral genome such that a low passage virus contain-
ing minimal accumulation of mutations derived from the infectious clone would be more
appropriate to study the immunopathogenesis in vivo. To this end, we constructed a full-length
infectious clone of the CVB3 genome and determined the complete nt sequence. We identified
three new nt substitutions that were not previously reported (C97U in the 5’ NTR; A4327G in
the 2C [silent]; and C5088U, resulting in a P1449L substitution in the 3A). We observed that
the infectious clone-derived virus induced significantly less severe myocardial damage but
comparable pancreatitis in relation to the disease phenotype induced by the wild type (Wt)
virus. Reversal of these mutations by generating three new infectious clones led us to identify a
viral strain that regains myocarditogenicity, suggesting that the mutations described above
might have collectively contributed to the attenuated myocarditis phenotype in the infected
animals.
Materials and Methods
Ethics Statement
Six-to-eight-week-old A/J, C57BL/6 and BALB/c mice were procured from the Jackson Labora-
tory (Bar Harbor, ME). The mice were maintained according to the animal protocol guidelines
of the University of Nebraska-Lincoln, Lincoln, NE; the Institutional Animal Care and Use
Committee of the University approved the experimental protocol (Permit number: A3459-01;
Protocol number: 973).
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Virus propagation, titration, and disease-induction
Vero cells (ATCC, Manassas, VA) grown to 80–90% confluence were infected with Wt CVB3
(Nancy strain, ATCC) as described previously [23]. Culture supernatants containing virus
were harvested after the complete cytopathic effect (CPE) was confirmed, and the viral stocks
were stored at -80°C until further use. After titrating the Wt and infectious clone-derived
viruses, tissue culture infective dose (TCID)50 values were determined according to the Spear-
man-Karber method [27]. To compare the viral titers of Wt and infectious clone-derived
viruses, Vero cells grown in 12-well plates were infected with viruses at multiplicity of infec-
tion (MOI), 0.1 and 3.0 in triplicates. After noting the CPE, viruses were harvested and titrated
as above. Similarly, the viral titers were determined in the target organs namely, hearts and
pancreata obtained from mice infected with Wt or infectious clone-derived virus. Briefly,
small pieces of tissues (hearts or pancreata) from two mice each, were pooled and homoge-
nized in sterile RPMI using the homogenizer, and the homogenate was centrifuged at 10,000
rpm for 15 minutes. After filtering the supernatant through a 0.2 μm sterile filter, the filtrate
was used to infect monolayers of Vero cells grown in 6-well plates. The passage 1 (P1) viruses
were harvested at 132 hours (heart samples), and 96 hours (pancreatic samples) postinfection.
The P1 virus samples were then used to determine the differences in the viral titers between
groups.
To infect mice, virus stock was diluted in 1x phosphate-buffered saline (PBS) to contain
2,000 TCID50/200 μl, and the inocula were administered intraperitoneally (i.p.), whereas the
control (uninfected) mice received only 1x PBS. Animals were housed in filter-top cages (2 to
3 mice/cage) assembled with closed air-circulation. Cages containing the chow diet and
waterers were changed once in 3 days until the termination of the experiment, and the ani-
mals had ad libitum access to food and water during the entire period of study. The animals
were observed for clinical signs such as ruffled fur, isolation from the group/sluggish activity
or self-mutilation and they were inspected twice a day, and body weights were taken daily.
Additionally, alternative food- and fluid-source, trans gel diet (ClearH2O, Portland, ME)
were placed in the cage floor as the animals started to show the clinical signs described above
regardless of whether the companion animals within the cage were sick or not. Hearts and
pancreata were collected from the animals that died naturally, and also from the animals
euthanized on days 5, 7, 10 or at termination on day 21, postinfection. Animals were eutha-
nized using CO2 chamber prefilled with 2% CO2, and spleens, lymph nodes, hearts and pan-
creata were then collected.
Histopathology
Hearts and pancreata were fixed by immersion in 10% phosphate-buffered formalin, and pro-
cessed for histological examination [28]. Briefly, three full-diameter heart sections were cut at
5 μm thickness and stained with hematoxylin and eosin (H and E). The sections were examined
by the board (American College of Veterinary Pathologists)-certified pathologist, Dr. David
Steffen blinded to treatment. Pathology scores were generated by enumerating the foci of
inflammation, necrosis, mineralization, and fibrosis. The individual scores were used to com-
pare the qualitative nature of the lesions. The total scores represent total foci of pathologic
change across the three sections of heart. Multiple changes present in a single focus were
counted as 1 in the total count [23,29]. The severity of pancreatic change was estimated as per-
cent of tissue section involvement from one random section of pancreas. The nature of pancre-
atic lesions was noted as atrophy, inflammation, mineralization and necrosis or a combination
of these [23,29].
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Derivation of full-length infectious cDNA clone of CVB3 and in vitro
transcription
To generate the infectious clone, we first generated a stock virus (passage 1) from a well-iso-
lated plaque of CVB3 (Nancy strain, ATCC) and then prepared RNA from the stock virus
using Trizol LS reagent (Invitrogen, Carlsbad, CA). We synthesized full-length cDNA using
Moloney murine leukemia virus-reverse transcriptase in a reaction mixture containing oligo-
dT (Invitrogen) and performed PCR with this cDNA to amplify two fragments using high-
fidelity Pfu polymerase (Agilent Technologies, Santa Clara, CA). The primer sets used in the
preparation of these amplicons are described in Table 1; the amplicons were cloned into plas-
mid pBR322 in a stepwise manner (Fig 1). To facilitate in vitro RNA transcription, bacterio-
phage T7 RNA polymerase promoter was inserted in the 5’ end of P1 primer next to the RsrII
site (Fig 1 and Table 1). The first fragment was digested with RsrII and PacI and cloned into a
modified pBR322 vector as described previously [30]. We digested this vector with SpeI and
PacI and gel-purified the plasmid DNA, into which we then cloned the second PCR fragment
digested with SpeI and PacI. This vector containing the full-length cDNA clone, hereafter des-
ignated, pBRCVB3 was sequenced leading us to identify three new nt changes that were not
reported previously (Table 2). For in vitro transcription, the pBRCVB3 vector was linearized
with PacI, and the transcription reaction was performed using T7 RNA polymerase at 37°C as
recommended by the manufacturer (Promega, Madison, WI).
Rapid amplification of cDNA ends (RACE)
To confirm viral sequences in the primers (P1 and P4) that flank the two ends of the full-length
cDNA (Table 1), we performed RACE on plaque-purified Wt CVB3 RNA. For 5’ RACE, viral
RNA was treated with tobacco acid pyrophosphatase to convert the 5’ tri-phosphate group to a
mono-phosphate group, and the RNA 5’ adapter oligo was then ligated to Wt CVB3 RNA
using RNA ligase (Epicenter, Madison, WI). cDNA was synthesized using the reverse primer
internal to the viral sequence at the 5’ NTR (5’ AACCGCGTGAGCAGTCTATTG 3’). Using
this cDNA mixture, we amplified a fragment of 266 bp by PCR using the 5’ adapter forward
primer (supplied) and the reverse primer internal to the viral sequence as indicated above, then
sequenced the PCR products. In 3’ RACE analysis, we first ligated the synthetic RNA 3’ adapter
(5’ [phos]ACAAGCACACCCGAAGCGA CCAGCGGCAGA[phos] 3’) to the 3’ end of viral
RNA using RNA ligase, modifying the oligo to include monophosphate groups at both the 5’
and 3’ ends to facilitate ligation and to avoid concatenation of oligos, respectively. After synthe-
sizing cDNA using the reverse primer internal to the 3’ adapter (5’ CGCTGGTCGCTTCGGGTG
3’), we performed PCR with Taq DNA polymerase, using the forward primer 5’ TGCAACT
CCCATCACCTGTACA 3’ (internal to the viral sequence) and the reverse 3’ adapter primer as
indicated above. After purifying, the PCR products were cloned into pGEMT-Easy vector (Pro-
mega), and seventeen clones were then sequenced.
Recovery of infectious virus from in vitro transcribed viral RNA
Vero cells grown to 80% confluence were trypsinized and washed twice with 1x PBS by centri-
fugation at 400xg for 6 minutes at room temperature (RT). Cells were resuspended in electro-
poration buffer (Biorad, Hercules, CA) to a cell density of 10x106 cells/ml. The in vitro
transcribed viral RNA (5μg) was taken in a 0.4 cm electroporation cuvette (Biorad), and cell
suspension (2x106 cells in 200 μl) was then added. The mixture was subjected to electropora-
tion using Gene Pulser Xcell Electroporation System at 160V (Biorad), according to the manu-
facturer’s recommendations. The electroporated cells were aspirated gently and transferred to
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6-well plates containing 2 ml of fresh EMEM/10% FBS prewarmed to 37°C. After 16 hours, the
medium was removed; cells were washed with 1x PBS and replaced with 2 ml of fresh EMEM/
2% FBS. Cells were incubated up to 4 days, and as the CPE became evident, supernatants con-
taining virus were harvested, passaged and titrated, and stored as above.
Table 1. Primer sets used to generate infectious cDNA clone, pBRCVB3.
Primer Sequence
Fragment 1
RsrII T7 promoter
P1 5’ATATATCGGACCG TAATACGACTCACTATAGGG TTAAAACAGCCTG TGGGTTGAT3’
PacI SpeI
P2 5’ATATTTAATTAATCTTGACCCACTAGTGATTCTTTC3’
Fragment 2
SpeI
P3 5’GAAAGAATCACTAGTGGGTCAAGA3’
PacI
P4 5’TATATATTAATTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTCGCACCGAATGCGGAGAATTTA3’
Underlined nt, restriction enzyme sites; overlined nt, T7 promoter; bold nt, viral sequence.
doi:10.1371/journal.pone.0131052.t001
Fig 1. Derivation of infectious CVB3 cDNA clone.Using cDNA synthesized from theWt CVB3 (Nancy)
virus RNA, overlapping fragments 1 and 2 were amplified by PCR to generate a full-length cDNA clone. While
RsrII and T7 RNA polymerase promoter sequences were inserted upstream of the 5’ NTR of fragment 1, the
poly(A) tail (59 adenosine residues) and PacI sequences were inserted downstream to the 3’ NTR of
fragment 2. The fragments were cloned into the pBR322 vector and sequenced. Vector map was derived
using SimVector software.
doi:10.1371/journal.pone.0131052.g001
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Creation of new infectious clone-derived viruses to revert the mutations
noted in pBRCVB3 virus
After sequencing and ascertaining the presence of three new nt changes—C97U in the 5’ NTR,
and A4327G and C5088U in the NS proteins 2C and 3A, respectively in pBRCVB3 virus
(Table 2)–we sought to revert these mutations by generating three new infectious cDNA clones
using pBRCVB3 as a backbone (S1 Fig). These include: 1) U97C fixed (pBRCVB3/97); 2)
G4327A and U5088C fixed (pBRCVB3/4327_5088); and 3) U97C, G4327A and U5088C fixed
(pBRCVB3/97_4327_5088). Derivation of these clones required the synthesis of gene segments
to be incorporated into pBRCVB3 (Genscript, Piscataway, NJ). To generate pBRCVB3/97, a
290 bp fragment containing the nt C at the desired position (97th) was cloned into RsrII (5’)
and BstBI (3’) sites in pBRCVB3. Likewise, a fragment (2036 bp) bearing the desired nt change
(A/4327 and C/5088) was cloned into pBRCVB3 at BssHII (5’) and BstEII (3’) sites to obtain
pBRCVB3/4327_5088. Finally, pBRCVB3/97_4327_5088 was obtained by cloning the frag-
ment (2036 bp) released from pBRCVB3/4327_5088 into pBRCVB3/97 after digesting with
BssHII and BstEII. The in vitro transcription procedures and the recovery of infectious viruses
were as described above.
Immunofluorescence
To verify infectivity of viruses derived from the infectious clones, we used CVB3 anti-serum
(ATCC) that allowed us to detect cells expressing viral proteins based on immunofluorescence
[21]. Briefly, Vero cells (2x105 cells/ml/well) were grown in triplicate on sterile coverslips in
Table 2. Nucleotide changes detected in the infectious clone, pBRCVB3.
Position Region nt changes* Amino acids References
35 5’ NTR G addition [21]
97 5’ NTR C to U Not reported
647 5’ NTR C to U [16]
667 5’ NTR U to C [16]
788 VP4 G to A Gly to Arg [16]
1180 VP2 A to G Gly (silent) [16,18,21]
1401 VP2 C to G Thr to Ser [16,18]
1402 VP2 G to C Thr to Ser [16,18]
1963 VP3 U to C Asn (silent) [16]
2201 VP3 G to A Val to Ile [16]
2438 VP3 G to C Glu to Gln [16]
2560 VP1 A to G Glu (silent) [16]
2593 VP1 C to U Thr (silent) [16]
2851 VP1 C to U Asp (silent) [16]
3346 VP1 A to G Val (silent) [16]
4177 2C A to G Glu (silent) [16]
4327 2C A to G Ala (silent) Not reported
5088 3A C to U Pro to Leu Not reported
7026 3Dpol U to C Val to Ala [16]
7334 3’ NTR C to U [16]
*Sequence comparisons were made between consensus sequence derived from the published sequences shown in parenthesis and pBRCVB3.
The first nt in column 3 represents consensus sequence, and the second nt represents pBRCVB3.
Bold text indicates nt changes not reported.
doi:10.1371/journal.pone.0131052.t002
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12-well plates overnight at 37°C. The monolayers were washed with sterile 1x PBS and infected
with the Wt (positive control), pBRCVB3, pBRCVB3/97, pBRCVB3/4327_5088, and
pBRCVB3/97_4327_5088 at MOI of 0.5 for 1.5 hours. After adsorption, inoculum was aspi-
rated and replaced with EMEM/2% FBS. Cells grown in medium alone were used as negative
controls. After incubating for 12 hours at 37°C, cells were washed and fixed in methanol/ace-
tone (1:1) at RT for 40 minutes. Cells were then washed thrice with sterile 1x PBS and incu-
bated with anti-CVB3 serum (1:200) in PBS containing 2.5% bovine serum albumin at RT for
one hour. After five washings with PBS/Tween 20 (PBST, 0.05%), cells were incubated with
fluorescein isothiocyanate (FITC)-conjugated secondary rabbit, anti-horse IgG (1:1000; Sigma-
Aldrich, St. Louis, MO) at RT for one hour. Finally, coverslips containing the cells were
washed, mounted and visualized under Nikon A1-Eclipse 90i confocal microscope system
(Nikon Instruments Inc-Americas, Melville, NY). Images were acquired sequentially at an exci-
tation/emission wavelength of 561.5 nm/553–618 nm laser-setup for pseudocolored “green”
channel (60x).
Statistical analysis
Viral titers were determined on days 4 and 6 postinfection for Wt CVB3 and its variants. The
data were tested not significant for normality by Lilliefors test [31]. Based on a non-normal dis-
tribution, the Kruskal-Wallis test [32] was applied, with subsequent contrasts between variants
with multiple test correction via Tukey’s honestly significant difference criterion [33]. A Gener-
alized Linear Mixed Model was created to determine differences in the body weights between
groups. Several covariance structures were used to calculate the relative quality for the model
as determined by the Akaike information criterion [34] corrected for finite sample sizes
(605.53 AICc 673.18). The Ante-Dependence had the best fit (AICc = 605.53), and it was
selected. The survival curves were analyzed via Cox Proportional Hazards Regression [35]. Dif-
ferences in the medians of myocardial lesions were analyzed by the non-parametric Wilcoxon
rank sum test [36]. One-way MANOVA analysis was performed to evaluate differences in pan-
creatitis. All statistical tests were performed in MATLAB (R2014b, The Mathworks Inc.,
Natick, MA, USA), except the test on body weights, which was performed using GLIMMIX
procedure in SAS (version 9.3, SAS Institute Inc., Cary, NC, USA).
Results and Discussion
CVB3 (Nancy) is a commonly used laboratory strain to study the immunopathogenesis of viral
myocarditis in various mouse models [22–25]. To verify the pathogenicity of the Wt virus, we
used A/J mice, which are highly susceptible to CVB3 infection [23,37,38]. We first noted that
the mice infected with 50 TCID50/animal developed myocarditis and pancreatitis accompanied
by necrosis as reported previously [22,23,25].
Since CVB3 is an RNA virus and the viral genome is prone to errors during continuous pas-
sage under experimental conditions [39], we sought to generate the infectious cDNA clone of
the virus to obtain a virus with a conserved genome sequence for further experimentation. To
accomplish this, we assembled the full-length cDNA clone, pBRCVB3, from two RT-PCR-
derived amplicons spanning the entire length of the viral genome. The PCR fragments were
cloned in the pBR322 vector to generate the full-length clone (Fig 1). Sequencing of three indi-
vidual full-length clones resulted in the derivation of the consensus viral sequence bearing
7399 nts (NCBI AC_JX312064.1).
Since we had designed primers (P1 to P4; Table 1) to construct an infectious cDNA clone
based on sequence information first deposited in the NCBI database [18], it was necessary to
verify the authentic sequences of the viral genome at the termini, as well as the viral sequences
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spanning the primers P2 and P3 (Fig 1). By employing the RACE technique, we obtained
sequences of the termini of the viral genome. Using RNA isolated from a virus stock prepared
from a single plaque-purified Wt virus, we determined that the viral sequences at both the 5’
and 3’ termini were identical to those present in the P1 and P4 primers (Table 1). Although,
based on the published literature [16], we had incorporated 59 adenosine residues at the end of
the 3’NTR in the infectious clone, our 3’ RACE analyses of 17 different clones revealed variable
poly(A) tail lengths ranging in size from 19 to 52 adenosine residues. Such variations in the
poly(A) tail length have been reported previously [16]. The 3’ RACE analysis also revealed the
presence of one additional G residue at the extreme 3’ terminus prior to the poly(A) tail, thus
making the full-length parental viral genome to be 7400 bases. Because it had previously been
shown that the presence or absence of this additional G residue in the viral genome does not
influence infectivity or pathogenicity of the virus [16,18,40,41], we did not incorporate this res-
idue into our infectious cDNA clone (pBRCVB3). Sequence analyses of the regions spanning
the P2 and P3 primers also revealed authentic sequences of the viral genome.
We then compared the sequence of our infectious clone, pBRCVB3, with previously pub-
lished CVB3 (Nancy strain) genome sequences [16,18,21]. We noted changes in 15, 61, and 23
nts corresponding to AC_M33854.1, AC_M16572.1, and AC_JN048468.1, respectively (S1
Table), but such changes are to be expected [17,18,21]. We then derived a consensus sequence
from the above three and compared it to the pBRCVB3 sequence, leading us to identify 20 nts
that were different. These included five nts in the NTRs (four in the 5’NTR and one in the 3’
NTR); 11 nts in the structural protein regions (one in VP4, three each in VP2 and VP3, and four
in VP1); and four nts in the NS protein regions (two in 2C and one each in 3A and 3D; Table 2).
Three of these have not been previously reported: C97U in the 5’NTR; A4327G, silent, in the
2C protein; and C5088U, resulting in P1449L substitution, in the 3A protein (Table 2).
Nucleotide variations in the structural and NS protein regions, including the 3’NTR, may
or may not alter the growth characteristics and pathogenicity of the virus [20,21,41–44]. How-
ever, alterations in the 5’ NTR have been identified as important molecular determinants of
viral virulence [10–12]. For example, a single nucleotide substitution of U to C, at position 234
attenuates cardiovirulence in mice [44]. Conversely, in a separate study, when 13 naturally
occurring isolates of CVB3 were tested for their pathogenicity, only two isolates were found to
be pathogenic—but all of them had U at position 234, suggesting that nt variations in other
positions in the 5’ NTR, if any, may influence virulence in the natural isolates [45]. Likewise, A
to U nt changes at positions 580 or 690 within the 5’NTR were found not to be critical for viral
attenuation [46]. Furthermore, comparison of sequences of the 5’ NTRs between myocarditic
and non-myocarditic CVB3 strains by computational analysis revealed variations in 23 posi-
tions; of these, 14 changes located within the four stem-loops of the secondary structures of
viral RNA were predicted to influence cardiovirulence [47]. In our infectious clone, one of the
four nt changes noted in the 5’ NTR at position 97 (C to U) had not been previously reported,
leading us to evaluate the virulence and pathogenic properties of the infectious cDNA clone-
derived virus (pBRCVB3 virus).
To determine the virulence of pBRCVB3 virus, we first recovered the virus from the infec-
tious clone following transfection of Vero cells with in vitro-transcribed RNA. After passaging
the virus twice in cultures (similar to Wt virus), we sought to determine its pathogenicity in
vivo. Groups of A/J mice were infected with 2000 TCID50/animal, and on days 5, 7, 10 or 21
postinfection, animals were euthanized; hearts and pancreata were evaluated for inflammatory
changes, and the lesions were compared with uninfected animals. Unexpectedly, in animals
infected with the infectious clone-derived virus, myocarditis was significantly attenuated
(Table 3). As shown in Fig 2A, myocarditis in mice infected with the Wt virus showed wide-
spread lesions containing necrosis, mineralization, and lymphocytic infiltrates as opposed to
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occasional lesions in pBRCVB3 virus-infected animals. Pancreatitis, however was consistently
present in both groups of animals with comparable severity as indicated by atrophic changes,
necrosis and inflammatory infiltrates (Fig 2B; Table 4). The finding that pBRCVB3 virus-
induced pancreatitis is comparable to Wt virus suggests that the virus did reach the target tis-
sues in infected animals. But, why then attenuated myocarditogenicity? One possible reason
could be that the tropism of pBRCVB3 virus containing the nt changes (C97U, A4327G, and
C5088U) might have been altered for the heart. To address this possibility, we determined the
viral titers from hearts and pancreata obtained from animals infected with Wt virus or
pBRCVB3 virus on days 5, 7 and 10 postinfection. The virus was found to be present in hearts
from animals infected with pBRCVB3 virus similar to Wt virus-infected group as the viral titers
were comparable at all the time-points postinfection (Fig 2C, left panel). Likewise, viral titers
from pancreata from both the groups were also comparable except that pBRCVB3 virus could
not be recovered on day 10 postinfection (Fig 2C, right panel).
We next asked whether the myocarditis-attenuating phenotype of pBRCVB3 virus can be
recapitulated in other mouse strains. To address this question, groups of C57BL/6 and BALB/c
mice were infected with Wt virus or pBRCVB3 virus, and hearts and pancreata were examined
for histological changes. The data revealed that myocarditis was completely absent in animals
infected with pBRCVB3 virus, whereas pancreatitis-severity was comparable in both C57BL/6
and BALB/c mice (Figures A and B of S2 Fig; S2 and S3 Tables). Furthermore, by evaluating
the viral titers from the target organs, we noted that the virus could be recovered from hearts of
both C57BL/6 and BALB/c mice on different days (5, 7 and 10) postinfection with the Wt
virus, whereas the pBRCVB3 virus could only be recovered up to day 5 and day 7 from C57BL/
6 and BALB/c mice, respectively (Figure C of S2 Fig). Of note, while the Wt virus could be iso-
lated up to day 5 from the pancreata derived from both C57BL/6 and BALB/c mice, the
pBRCV3 virus could be isolated up to day 7 from both the strains (S2C Fig). Taken together,
the data suggest that the pBRCVB3 virus carrying the three nt substitutions (C97U, A4327G
and C5088U) represent an attenuated variant of CVB3 with a selective loss of myocarditis-
inducing ability.
To test this hypothesis, we derived three new infectious cDNA clones using pBRCVB3 as a
backbone by reverting the mutations (S1 Fig). These include pBRCVB3/97 (U97C), pBRCVB3/
4327_5088 (G4327A and U5088C), and pBRCVB3/97_4327_5088 (U97C, G4327A and
U5088C). First, we recovered the infectious viruses from all the clones, and after passaging
twice in Vero cells, ascertained the expression of viral proteins by immunofluorescence using
Wt virus as a positive control, and media containing uninfected cells as negative controls. Fig
3A shows that Vero cells infected with the Wt virus and the clone-derived viruses exhibited
Table 3. Histological evaluation of hearts in mice infected with different CVB3-variants.
Group Incidence Mortality† Myocardial lesions
CVB3 Wt 14 / 15 (93.33) 8 / 12 (66.67) 68.47 ± 11.18
pBRCVB3 13 / 17 (74.47) 5 / 11 (45.45) 3.71 ± 1.21a
pBRCVB3/97 9 / 20 (45.00) 7 / 20 (35.00) 8.50 ± 3.88a
pBRCVB3/4327_5088 7 / 13 (53.85) 7 / 13 (53.85) 26.38 ± 11.75a
pBRCVB3/97_4327_5088 11 / 12 (91.67) 4 / 12 (33.33) 47.17 ± 18.95b
†represents natural deaths;
() indicates percentages;
a, denotes significant differences in comparison with the CVB3 Wt (p<0.03);
b, denote significant differences in comparison with the pBRCVB3/97 (p = 0.04)
doi:10.1371/journal.pone.0131052.t003
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Fig 2. Myocarditis severity is attenuated in mice infected with the infectious clone-derived virus,
pBRCVB3. Histology. A/J mice were infected with Wt virus or the virus derived from pBRCVB3 i.p., and
hearts and pancreata were harvested at termination on day 21 postinfection or as the animals died or
euthanized. The tissues were examined by H and E staining. Representative sections from three individual
animals infected with Wt virus or pBRCVB3 virus are shown (n = 15 to 17 mice per group), whereas the
sections obtained from uninfected animals were used as controls. (A) Hearts. Top panel (control group):
heart section from uninfected animal without inflammation, mineralization or necrosis; middle panels (Wt
virus-infected): extensive infiltrates of macrophages and lymphocytes into the myocardium filling areas of
myocardial cell loss/necrosis (Mouse 1), extensive large foci of necrosis and mineralization surrounded by
inflammation consisting of macrophages and lymphocytes (Mouse 2), multiple small foci of necrosis and
mineralization infiltrated by a few inflammatory cells (Mouse 3); bottom panels (pBRCVB3 virus-infected):
small focal inflammatory infiltrates into myocardium (Mouse 1), a small foci of necrosis in the myocardium
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viral protein expression, but not in medium control, suggesting that all viral variants retained
the infectivity similar to the Wt virus. We next determined the viral titers at MOIs of 0.1 and 3,
and the data revealed no significant differences between groups except that the titers obtained
from pBRCVB3/97_4327_5088 virus tended to be lower than those obtained from the Wt virus
on day 4, only at MOI of 3 (Fig 3B). Together, the data suggest that the nt variations present in
the three new infectious clones do not adversely affect viral recovery and their corresponding
viruses retain viral infectivity.
To determine virulence of the newly generated viruses, groups of animals were infected with
the Wt virus or its variants and monitored for loss of body weight and mortalities. Generally,
acutely infected animals lose body weight and die within approximately 10 days postinfection,
and not surprisingly, variations in loss of body weight were noted between groups over a period
of time (p = 0.04). As shown in Fig 4 (left panel), the body weight loss tended to be more dra-
matic in animals infected with the Wt virus compared with other groups, in particular in ani-
mals infected with the viruses derived from pBRCVB3/97 (p = 0.04) and pBRCVB3/
97_4327_5088 (p = 0.05). Likewise, mortalities as shown by survival curves also tended to be
greater in animals infected with the Wt virus (67%) as compared with other groups (33 to
54%), but the differences were insignificant (Fig 4, right panel; Table 3). At termination on day
21 (or as animals died), hearts and pancreata from the infected animals were examined to ver-
ify the severity of myocarditis (Table 3) and pancreatitis (Table 4).
All animals infected with the Wt virus or its variants showed myocardial damage with an
incidence of 45% to 93%. The histological changes include inflammation, necrosis, mineraliza-
tion and fibrosis, with necrosis being a prominent lesion. Similarly, pancreatitis was consis-
tently seen in all the groups with an incidence of 94% to 100%. While the hearts and pancreata
from uninfected mice showed normal structural features (Fig 5Ai, and 5Bi), animals infected
with the Wt virus showed lymphocytic infiltrates and hemorrhagic necrosis in the myocardium
including widespread atrophic changes in the pancreatic acini and pancreatic necrosis, all of
which are expected changes in CVB3 infection (Fig 5Aii, and 5Bii) [22,23]. Likewise, the
(Mouse 2), small foci of lymphocytic inflammation (Mouse 3). (B) Pancreata. Top panel (control group):
pancreas from an uninfected animal showing intact islets; middle panels (Wt virus-infected): diffuse atrophy
with scattered lymphocyte infiltrates (Mouse 1), acute necrosis, mineralization and inflammation (Mouse 2),
diffuse marked atrophy with mild diffuse inflammation (Mouse 3); bottom panels (pBRCVB3 virus-infected):
diffuse atrophy and lymphocytic infiltrates (Mouse 1), diffuse necrosis with pyknotic nuclei (Mouse 2), diffuse
atrophy with mild inflammation (Mouse 3). Arrows indicate the lesions (N, necrosis; M, mineralization; and I,
inflammation). Original magnification: 10x (hearts) and 40x (pancreata). (C) Viral titers. Hearts and
pancreata obtained from the above groups on days 5, 7 and 10 postinfection were processed for determining
the viral titers as described in the ‘methods’ section and the titers were compared between groups. Left panel,
hearts; right panel, pancreata.
doi:10.1371/journal.pone.0131052.g002
Table 4. Histological evaluation of pancreata in mice infected with different CVB3-variants.
Group Lesions
Incidence Atrophy Inflammation Necrosis Mineralization
CVB3 Wt 17 / 18 (94.44) 14 / 18 (77.78) 17 / 18 (94.44) 6 / 18 (33.33) 6 / 18 (33.33)
pBRCVB3 17 / 17 (100.0) 13 / 17 (76.47) 15 / 17 (88.24) 8 / 17 (47.06) 7 / 17 (41.18)
pBRCVB3/97 20 / 20 (100.0) 16 / 20 (80.00) 15 / 20 (75.00) 5 / 20 (25.00) 5 / 20 (25.00)
pBRCVB3/4327_5088 11 / 11 (100.0) 7 / 11 (63.63) 11 / 11 (100.0) 5 / 11 (45.45) 4 / 11 (30.76)
pBRCVB3/97_4327_5088 9 / 9 (100.0) 9 / 9 (100.0) 6 / 9 (66.66) 3 / 9 (33.33) 3 / 9 (33.33)
() represents percentages
doi:10.1371/journal.pone.0131052.t004
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animals infected with pBRCVB3 virus also had severe pancreatitis similar to Wt virus-infected
animals (Fig 5Biii), but the myocarditis severity was significantly low (Fig 5Aiii; Tables 3 and
4). In contrast, animals infected with the viruses generated from the newly derived infectious
clones, pBRCVB3/97, pBRCVB3/4327_5088, or pBRCVB3/97_4327_5088, showed pancreati-
tis similar to that of Wt virus (Fig 5Biv, 5Bv and 5Bvi), but the severity of myocarditis varied in
decreasing order from pBRCVB3/97_4327_5088 (Fig 5Avi), followed by pBRCVB3/4327_5088
(Fig 5Av), then pBRCVB3/97 viruses (Fig 5Aiv), leading us to make three observations: 1)
myocarditis severity was greater in animals infected with the Wt virus, compared to those
infected with the viruses derived from the parental infectious clone (pBRCVB3; p = 0.0013) or
two of its newly derived variants, pBRCVB3/97 (p = 0.0001) or pBRCVB3/4327_5088
(p = 0.0248), but not those in the pBRCVB3/97_4327_5088 virus-infected group (Table 3); 2)
the severity of myocarditis induced with pBRCVB3/97 or pBRCVB3/4327_5088 viruses did
not differ from that induced with pBRCVB3 virus, suggesting that reversion of the mutations
Fig 3. Infectivity of viruses derived from various infectious cDNA clones. (A) Detection of infectivity by immunofluorescence technique. Vero cells
grown in monolayers on coverslips were cultured further in the medium alone or infected with EMEM containing CVB3Wt, pBRCVB3, pBRCVB3/97,
pBRCVB3/4327_5088, or pBRCVB3/97_4327_5088 in 12-well plates. After 12 hours of incubation at 37°C, cells were fixed, incubated with anti-CVB3 serum
followed by secondary FITC-conjugated IgG to detect the viral antigens. The coverslips were washed and mounted and examined by Laser Scanning
Confocal Microscope. Top panel: phase-contrast images. Bottom panel: immunofluorescence images. Original magnification: 60x. (B) Comparison of viral
titers.Monolayers of Vero cells were grown to 80% confluence in 12-well plates. Triplicate wells were infected with MOI of 0.1 or 3 of P2 viruses of CVB3Wt,
pBRCVB3, pBRCVB3/97, pBRCVB3/4327_5088, or pBRCVB3/97_4327_5088. After noting the CPE, the respective viral supernatants were harvested and
the viral titers (TCID50) were determined by Spearman-Karber method. Mean ± SEM values are shown (n = 3).
doi:10.1371/journal.pone.0131052.g003
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U97C and G4327A and U5088C in the respective clones individually did not influence the dis-
ease outcome; and 3) the disease severity induced by pBRCVB3/97_4327_5088 virus differed
from that induced by pBRCVB3 virus (Table 3), indicating that reversion of two mutations
(U97C and U5088C) together was critical to regain myocarditogenicity. However, A4327G in
the parental clone (pBRCVB3) did not seem to contribute to the disease pathogenesis since it is
a silent mutation, but the mechanistic basis for such an alteration in disease severity remains to
be determined.
Fig 4. Body weight loss andmortalities in mice infected with viruses derived from different infectious
cDNA clones. A/J mice infected with the indicated viruses were monitored for loss of body weight and
mortalities. Body weights measured in grams on days 0, 3, 5, 6, 10, 13 and 14 were plotted. Mean ± SEM
values derived from two individual experiments, each involving 6 to 7 animals per group, are shown (left
panel). The number of animals that died in each group was noted (n = 11–20 mice per group), and survival
curves were then derived using GraphPad Prism 6 software (right panel).
doi:10.1371/journal.pone.0131052.g004
Fig 5. Reversion of mutations in parental infectious clone-derived virus, pBRCVB3, rescues the myocarditis phenotype.Groups of 6- to 8-week old
female A/J mice were infected with Wt virus or pBRCVB3, pBRCVB3/97, pBRCVB3/4327_5088, or pBRCVB3/97_4327_5088 virus. At termination on day 21
postinfection or as the animals died, hearts and pancreata were collected for histological evaluation of inflammatory changes by H and E staining. (A) Hearts
from uninfected mice showed no apparent changes (i). Wt virus-infected mice showed widespread hemorrhagic necrosis and lymphocytic infiltrations (ii),
whereas pBRCVB3 virus-infected mice had focal myocardial necrosis (iii), as opposed to hemorrhagic necrosis seen in mice infected with pBRCVB3/97 and
pBRCVB3/4327_5088 viruses (iv and v) and hemorrhagic necrosis and lymphocytic infiltrations in pBRCVB3/97_4327_5088 virus-infected mice (vi). (B)
Pancreata from the corresponding groups as described above are shown (uninfected normal pancreas [i] and widespread atrophic changes, necrosis and
lymphocytic infiltrations [ii to vi]). Arrows indicate the lesions (N, necrosis; I, inflammation; and A, atrophy). Original magnification: 40x. n = 11 to 20 mice per
group.
doi:10.1371/journal.pone.0131052.g005
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In summary, we have described construction of an infectious clone of CVB3, whose geno-
mic sequence analysis revealed three novel nt changes, one of which (C97U) was found in the
5’ NTR, and the other two, A4327G, and C5088U, were noted in 2C and 3A proteins, respec-
tively, of CVB3. By characterizing the pathogenic attributes of virus generated from the infec-
tious clone, we noted that two mutations—C97U in the 5’NTR, and C5088U in the NS 3A
protein—might have contributed to the attenuated myocarditis phenotype associated with
pBRCVB3 virus. Although the other mutation, A4327G in 2C protein, is a silent mutation, we
decided to revert it anyway because the CVB3 containing this mutation had not been previ-
ously reported. Literature indicates that both attenuated and cardiovirulent strains of CVB3
can replicate and generate infectious viral particles in vitro, but they may or may not be patho-
genic in vivo [12,13,44]. The finding that the pBRCVB3 virus bearing C97U and C5088U
showed selective attenuation of disease in the heart but not in pancreas suggests that the occur-
rence of mutations can differentially contribute to viral virulence by organ type. The availabil-
ity of such tools may permit us to determine the molecular mechanisms of differential organ-
specific disease phenotypes in future studies. It is possible that CVB3 strains possessing such
altered nts may evolve naturally, and such alterations may favor the survival of avirulent strains
of viruses in the environment.
Supporting Information
S1 Fig. Location of mutations in the infectious cDNA clones. Left panel indicates the loca-
tion of nts U, G and U at positions, 97, 4327 and 5088, respectively, in parental infectious
cDNA clone. Right panel indicates the location of reverted nts U to C, G to A, and U to C, at
positions, 97, 4327 and 5088, respectively, in the newly generated infectious cDNA clones. Vec-
tor maps were derived using SnapGene software.
(TIF)
S2 Fig. The attenuated myocarditis-phenotype induced with the infectious clone-derived
virus, pBRCVB3 was recapitulated both in C57BL/6, and BALB/c mice. Groups of C57BL/6
and BALB/c mice were infected with Wt virus or pBRCVB3 virus. Animals were euthanized on
days 5, 7, and 10 postinfection, and hearts and pancreata were collected for histological exami-
nation by H and E staining. (Figure A) Hearts. Section from C57BL/6 mice infected with Wt
virus showing a necrotic fiber (arrow) surrounded by a few lymphocytes (i), as opposed to
apparently normal heart from pBRCVB3 virus-infected animal (ii). Similarly, BALB/c mice
showed hyper-eosinophilic necrotic fibers with pyknotic nuclei surrounded by a few lympho-
cytes (arrow; iii), whereas animals infected with pBRCVB3 virus had apparently normal hearts
(iv). (Figure B) Pancreata. Four representative sections are shown, two each for C57BL/6 and
BALB/c mice. C57BL/6: Wt virus-infected animal showing diffuse necrosis and inflammation
(i); and pBRCVB3 virus-infected animal showing diffuse necrosis, inflammation, and minerali-
zation (ii). BALB/c mice: Animal infected with Wt virus showing foci of lymphocytic inflam-
mation in atrophied pancreas (iii), as opposed to diffuse inflammation with atrophied pancreas
in pBRCVB3 virus-infected mouse (iv). Original magnification, 40x. n = 6 per group.
(Figure C) Viral titers.Hearts and pancreata harvested from the above groups were processed
for determining the viral titers as described in the methods section. Top panels: Heart and pan-
creata from C57BL/6 mice; bottom panels: Heart and pancreata from BALB/c mice.
(TIF)
S1 Table. List of nucleotide changes detected in pBRCVB3 in comparison with other Nancy
strains of CVB3.
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S2 Table. Histological evaluation of hearts from C57BL6 and BALB/c mice infected with
CVB3Wt and pBRCVB3.
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S3 Table. Histological evaluation of pancreata from C57BL6 and BALB/c mice infected
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